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OBJECTIVE: Aneurysmal subarachnoid hemorrhage puts patients at high risk for the development of pituitary
insufficiency. We evaluated the incidence of pituitary dysfunction in these patients and its correlation with
clinical outcome.
METHODS: Pituitary function was tested in 66 consecutive patients in the first 15 days after aneurysmal
subarachnoid hemorrhage. The following were measured in all patients: thyroid-stimulating hormone, free
thyroxine, triiodothyronine, luteinizing hormone, follicle-stimulating hormone, total testosterone (in males),
estradiol (in females), prolactin, serum cortisol, plasma adrenocorticotropic hormone, growth hormone and
insulin growth factor.
RESULTS: The endocrine assessment was made at a mean of 7.4 days (standard deviation ¡6.6) after
subarachnoid hemorrhage. Forty-four (66.7%) female and 22 (33.3%) male patients were evaluated. Thirty-nine
patients (59.1%) had some type of pituitary dysfunction. Follicle-stimulating hormone/luteinizing hormone
deficiency was the most frequent disorder (34.8%), followed by growth hormone/insulin growth factor
(28.7%), adrenocorticotropic hormone (18.1%) and thyroid-stimulating hormone (9%). Seventeen (25.7%)
patients showed deficiencies in more than one axis. A greater incidence of hormone deficiency was observed in
patients with a Glasgow Coma Scale score #13 (t test, p = 0.008), Hunt-Hess grade $4 (t test, p,0.001), or Fisher
grade 4 (t test, p = 0.039). Hormone deficiency was not significantly associated (p.0.05) with increased
hospitalization or clinical outcome.
CONCLUSION: Pituitary dysfunction was identified in a substantial portion of patients with previous aneurysmal
subarachnoid hemorrhage, but no association was found between this dysfunction and poor clinical outcome.
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& INTRODUCTION
Spontaneous subarachnoid hemorrhage (SAH) is a disease
with high morbimortality that affects the economically active
population. Its six-monthmortality rate ranges from 40 to 50%.
In recent years, research has focused on factors related to
diminished quality of life in patients with SAH and with good
neurological recovery (1,2). One of these factors is neuroendo-
crine dysfunction following SAH. Nonspecific symptoms
that occur frequently and can provoke important limita-
tions include fatigue, headaches, mood swings, depression,
cognitive impairment and reduced independence in daily
activities, which may be related to hypopituitarism (3-6).
Some evidence of the relationship between pituitary
dysfunction and SAH has been reported in the literature. A
number of studies have suggested that endocrine disorders
are caused by compression of the hypothalamus-pituitary
complex by the aneurysm. Other reported causes are the
SAH itself due to perfusion alterations, toxins from extra-
vasated blood, ischemia due to vasospasm, increased
intracranial pressure, and hydrocephalus. One additional
cause is injury during the surgical procedure (6-9).
Determining the incidence and prevalence of hypopitui-
tarism in patients with SAH is fundamental because this
would permit the study of more effective measures to
improve the quality of life of patients with this serious
disease (4,6,10,11). The main objective of this study was to
evaluate the incidence of hypopituitarism in the first 15 days
after SAH to assess its implications for prognosis and
hospitalization period.
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& MATERIALS AND METHODS
Patients
This study evaluated 66 patients admitted to the
Neurosurgical Service of Santa Casa Hospital at Belo
Horizonte between December 2009 and December 2010
with a diagnosis of SAH secondary to cerebral aneurysm
rupture, which was confirmed by CT scan and digital
subtraction cerebral angiography (DSA) of the four vessels.
Clinical evaluation was performed at admission using the
Glasgow Coma Scale (GCS). SAH severity was graded
clinically using the Hunt-Hess scale (HH) and radiologically
using the Fisher scale. The presence of hydrocephalus was
recorded at the time of discharge. Clinical outcome was
evaluated by the Glasgow Outcome Scale (GOS) at hospital
discharge by one of the authors; a score of 4 or 5 was
considered a favorable outcome, and 1 to 3 was considered a
poor outcome.
The inclusion criteria were SAH secondary to ruptured
aneurysm, an absence of endocrine changes prior to
hormone data collection (performed within the first 15 days
after SAH) and patient age $18 years. The exclusion criteria
were patients younger than 18 years, more than 15 days
since the ictus of SAH, those with prior endocrine
dysfunction, those who refused endocrine tests, patients
whose data were not collected properly and those who had
recent or prolonged use of corticosteroids. Out of the 93
patients initially assessed, 27 were excluded: 1 due to age, 3
for prior endocrine dysfunction, 5 for previous use of
corticosteroids (steroid administration is still a common
practice in many units) and 18 due to a lack of complete
hormone data (some patients required urgent surgery;
therefore, complete endocrine assessment was impossible)
or evaluation more than 15 days after SAH. The resulting
study population consisted of 66 patients. None of these
patients presented severe liver disease, coronary heart
disease, kidney disease, severe depression or uncontrolled
diabetes mellitus.
Endocrine function testing
Blood samples for hormonal assessment were collected on
the first morning after admission after the patient had fasted
for at least 8 hours, when this practice would not
compromise the surgical decision. The endocrine assess-
ment was performed at a mean of 7.4 days (SD¡6.6) after
ictus. Posterior pituitary deficiency was not evaluated.
We used commercially available kits to determine
hormone levels. Morning cortisol, morning adrenocortico-
tropic hormone (ACTH), growth hormone (GH), insulin
growth factor (IGF-1), thyroid-stimulating hormone (TSH),
free thyroxine (fT4), total triiodothyronine (T3), follicle-
stimulating hormone (FSH), luteinizing hormone (LH),
estradiol (for women), testosterone (for men) and prolactin
were measured using chemiluminescence or immunoassay
methods. The reference values were appropriate for patient
age and sex in accordance with the manufacturer’s
recommendations. The hormonal levels obtained, together
with the respective methods and reference values, are
presented in Table 1.
The following criteria were used to diagnose hormonal
disturbances:
- ACTH deficiency was diagnosed based on low cortisol
associated with low or inappropriately normal ACTH.
- GH deficiency was diagnosed based on low IGF-1.
- TSH deficiency was defined as decreased fT4 in the
presence of inadequately low basal TSH.
- Prolactin disturbance was diagnosed based on high
prolactin.
- Gonadotropin deficiency was diagnosed based on basal
LH and FSH levels, testosterone levels in men, and estradiol
levels and the presence of menstrual disturbances in women.
Because there is no consensus regarding endocrine
assessment and treatment after SAH, hormone reposition
therapy was not performed in our series.
Statistical analysis
Statistical analysis was performed using the Statistical
Package for the Social Sciences Base Version 9.0 for
Windows, SPSS Inc. 1998, Chicago, IL). Mann-Whitney U
tests were performed for rank-ordered variables, chi-square
tests for categorical variables, and t tests for variables
counted on an interval scale. Bivariate correlations were
calculated with Pearson correlation coefficients.
Ethics
This study was performed in accordance with the ethical
standards of the responsible committee on human experi-
mentation of Santa Casa de Belo Horizonte and the Helsinki
Declaration of 1975 (1983 revision). Written informed
consent was obtained from the patients or someone
responsible for them.
& RESULTS
Sixty-six patients were evaluated; 44 (66.7%) were female.
The mean patient age was 48.3¡13.8 years (25-83 years).
Admission data, including the Hunt-Hess scale, Fisher
grade and neurological outcome, are presented in Table 2.
Fifty-four out of the 66 patients (81.8%) were submitted to
microsurgical clipping, and the remainder underwent
endovascular occlusion of the aneurysm. The mortality rate
was 15.1% (n= 10). Twenty-five (37.8%) patients had an
adverse outcome (GOS 1-3).
Endocrinological disorders
The endocrine assessment was made at a mean of 7.4 days
following SAH. The incidence of some degree of hypopi-
tuitarism after aneurysmal SAH was 59.0% (39 patients).
FSH/LH deficiency was the most frequent disorder (34.8%),
followed by GH/IGF-1 (28.7%), ACTH (18.1%), and TSH
(9%). Five (9%) patients presented high prolactin. Seventeen
(25.7%) patients showed disturbances in more than one axis.
The profile of pure hormone disturbances and multiple
hormone disturbances is detailed in Table 3.
Corticotrophic axis
Cortisol levels below 4 mg/dl associated with low or
inappropriately normal ACTH, which was compatible with
secondary adrenal deficiency, was detected in 8 patients
(12.1%), 5 (62.5%) of whom were female. The mean age of
these patients was 42.7¡8.4 years (25-52 years). The
mortality rate was 25.0% (n = 2). Patient evolution was
favorable in 5 (64.5%) cases and poor in 3 (37.5%).
Somatotrophic axis
Low IGF-1 levels were detected in 19 (28.7%) patients, of
whom 16 (84.2%) were female. Their mean age was
51.4¡13.2 years (27-77 years), and their mortality rate was
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26.3% (n= 5). Clinical evolution was favorable in 12 (63.2%)
patients and poor in 7 (36.8%).
Thyroid-stimulating hormone (TSH)–free T4 axis
Low TSH was detected in 6 (9.0%) patients, 4 (66.7%) of
whom were female. Their mean age was 41.3¡3.8 years (36-
47 years). None of the patients with low TSH presented low
free T4 or T3. One patient with low TSH presented high free
T4. The mortality rate in the group with low TSH was 16.7%
(n= 1). Clinical evolution was favorable in 3 (50%) patients
and poor in 3 (50%).
Prolactin
High prolactin was detected in 6 (9%) patients, 5 (83.3%)
of whom were female. Its incidence was 4.5% in men and
11.3% in women. The mean age of this group was 49.8¡4.5
years (45-58 years), and the mortality rate was 0% (n= 0).
Clinical evolution was favorable in 4 (66.7%) patients and
poor in 2 (33.3%).
Gonadotropic axis
Low FSH/LH was detected in 23 (34.8%) patients, 14
(60.8%) of whom were female. Their mean age was
47.8¡15.4 years (25-83 years). Their mortality rate was
26.1% (n= 6). Clinical evolution was favorable in 14 (60.9%)
patients and poor in 9 (39.1%).
Among men, low testosterone levels were detected in 13
(59.1%) patients. The mean age of men with low testosterone
was 46.3¡10.5 years (25-61 years), and their mortality rate
was 30.8% (n= 4). Clinical evolution was favorable in 7
(53.8%) patients and poor in 6 (46.2%).
Among women, low estradiol was detected in 13 (29.5%)
patients. The mean age of women with low estradiol was
50.6¡16.9 years (26-83 years), and their mortality rate was
23.1% (n= 3). Clinical evolution was favorable in 7 (53.8%)
patients and poor in 6 (46.2%).
Endocrinological disorders versus clinical
assessment and outcome
A greater incidence of hormone deficiency was observed
in patients with GCS #13 (t test, p= 0.008), in patients with a
Hunt-Hess grade $4 (t test, p,0.001), and in patients with a
Fisher grade of 4 (t test, p= 0.039).
Hormone deficiency was not significantly associated
(p.0.05) with a longer hospitalization period. Poor outcome
(GOS 1-3) was observed in 41.0% (n = 16) of the patients
with hormonal deficiency compared with 33.3% (n= 9) in
the group with no hormonal change (p.0.05).
No statistically significant difference was verified
(p.0.05) in the hospitalization period or outcome in the
hormonal subgroups (Table 3).
& DISCUSSION
The pathophysiology of neuroendocrine dysfunction
following aneurysmal subarachnoid hemorrhage remains
Table 1 - Hormonal evaluations, with their respective methods and reference values.
Hormone Method Reference value Kit
Cortisol (morning) Chemiluminescence 4.3 to 22.4 mg/dL Beckman CoulterH
ACTH (morning) Chemiluminescence 0 to 46 pg/mL SiemensH
GH Chemiluminescence 0 to 0.5 ng/mL SiemensH
IGF-1 Chemiluminescence 91 to 246 ng/mL SiemensH
TSH Chemiluminescence 0.35 to 5.5 mcUI/mL Beckman CoulterH
Free T4 Chemiluminescence 0.7 to 2.0 ng/dL Beckman CoulterH
T3 Chemiluminescence 0.6 to 1.81 ng/mL Beckman CoulterH
FSH Chemiluminescence Women: Beckman CoulterH
Follicular phase: 2.5 to 10.2 mIU/mL
Mid-cycle: 3.4 to 33.4 mIU/mL
Luteal phase: 1.5 to 9.1 mIU/mL
Postmenopause: 23.0 to 116.3 mIU/mL
Men: 1.4 to 18.1 mIU/mL
LH Chemiluminescence Women: Beckman CoulterH
Follicular phase: 1.9 to 12.5 mIU/mL
Mid-cycle: 8.7 to 76.3 mIU/mL
Luteal phase: 0.5 to 16.9 mIU/mL
Postmenopause: 15.9 to 54.0 mIU/mL
Men:
Aged 20 to 70 years: 1.5 to 9.3 mIU/mL
Over 70 years: 3.1 to 34.6 mIU/mL)
Prolactin Chemiluminescence Women: Beckman CoulterH
Nonpregnant: 2.8 to 29.2 ng/mL
Pregnant: 9.7 to 208.5 ng/mL
Postmenopause: 1.8 to 20.3 ng/mL;
Men: 2.1 to 17.7 ng/mL
Total testosterone Immunoassay Men (18 to 60 years): 241 to 827 ng/dL Beckman CoulterH
Free testosterone Immunoassay Men (18 to 60 years): 6.2 to 28.1 pg/mL Beckman CoulterH
Estradiol Chemiluminescence Women: Beckman CoulterH
Follicular phase: 18.9 to 246.7 pg/mL
Mid-cycle: 35.5 to 570.8 pg/mL
Luteal phase: 22.4 to 256 pg/mL
Postmenopause: ,30 pg/mL
ACTH, adrenocorticotropic hormone; GH, growth hormone; IGF-1, insulin growth factor; TSH, thyroid-stimulating hormone; fT4, free thyroxine; T3, total
triiodothyronine; FSH, follicle-stimulating hormone; LH, luteinizing hormone.
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unknown. Some studies have suggested that ischemic or
hemorrhagic lesions in the hypothalamus or pituitary gland
may be the genesis of such changes (6).
The incidence and prevalence of neuroendocrine dysfunc-
tion have been the focus of research on some neurological
diseases, such as SAH and traumatic brain injury (TBI), and,
to a lesser extent, in radiation therapy on the central nervous
system, ischemic stroke and neurosurgical procedures for
non-pituitary tumors (7,8,12-16).
Previous studies have investigated pituitary dysfunctions
in the late period of the first days and the first hours after
SAH. The present study analyzed the first 15-day period
and detected a high incidence of hypopituitarism (59% of
the cases). We observed that FSH/LH deficiency was the
most prevalent disorder (34.8%), followed by GH/IGF-1
(28.7%), ACTH (18.1%) and TSH (9%). Seventeen (25.7%)
patients showed deficiencies in more than one axis. Our
results are similar to Klose et al. (17), who analyzed
hormonal changes in 26 patients at a mean of 7 days
following SAH and detected an incidence of pituitary
alterations of 58%. Klose et al. (17) detected low FSH/LH
in 93.3% of patients, low T3 in 35%, low cortisol in 12% and
low GH/IGF-1 in 15%.
In our analysis, patients who presented a more severe
clinical status on the HH and GCS evaluations and greater
bleeding on tomography (Fisher grade) showed a higher
propensity for endocrinological disorders. Klose et al. (17)
observed a correlation between lower GCS and the presence
of hydrocephalus with hormonal changes in the first days
after SAH. Schneider et al. (6) did not find a statistically
significant relationship between HH or Fisher grade and
endocrinological disorders in the late period after SAH. We
did not find a relationship between the presence of
hydrocephalus and endocrine changes. We also did not
find a correlation between the incidence of neuroendocrine
dysfunction and clinical outcome. This finding may be
explained at least in part by the selection bias. Our service is
a reference center, and most patients are admitted after the
first days of SAH. Our endocrinological assessment was
performed at a mean of 7.4 days, which favored the
inclusion of patients with a good neurological outcome
and most likely a better clinical state on admission.
Furthermore, the limited number of patients combined with
the significant amount of stratification (generating even
small subgroups of hormone deficiency) may have resulted
in a reduced power of the statistical analyses.
Mangieri et al. (18) studied the hormonal profiles of
patients in the hyperacute phase of SAH (the first 24 hours).
They observed an increase in cortisol in all patients studied
(n = 35), most likely due to the physiological response to
Table 2 - Demographic and clinical data of the study population.
-- General With dysfunction Without dysfunction p-value
N 66 (100%) 39 (59%) 27 (41%)
Age, years 48.3¡13.8 47.9¡13.4 49.0¡14.7 .0.05
Sex .0.05
Male 22 (33.3%) 14 (35.8%) 8 (29.6%)
Female 44 (66.6%) 25 (64.1%) 19 (70.3%)
Hospitalization duration, days 19.9¡19.1 20.6¡13.4 18.9¡25.2 .0.05
Treatment modality
Clipping 54 (81.8%) 31 (79.4%) 23 (85.1%) .0.05
Coils 12 (18.1%) 8 (20.5%) 4 (14.9%)
Hydrocephalus 7 (10.6%) 5 (12.8%) 2 (7.4%) .0.05
GCS 13.8¡2.5 13.2¡3.1 14.7¡0.6 0.008 ECG#13
Hunt-Hess
I 32 (48.4%) 16 (41.0%) 16 (59.2%) ,0.001
II 15 (22.7%) 10 (25.6%) 5 (18.5%) HH$4
III 13 (19.6%) 9 (23.0%) 4 (14.8%)
IV 4 (6.0%) 2 (5.1%) 2 (7.4%)
V 2 (3.0%) 2 (5.1%) 0 (0%)
Fisher
I 7 (10.6%) 3 (7.6%) 4 (14.8%) 0.039
II 14 (21.2%) 8 (20.5%) 6 (22.2%) Fisher$4
III 33 (50.0%) 18 (46.1%) 15 (55.5%)
IV 12 (18.1%) 10 (25.6%) 2 (7.4%)
GOS
1-3 25 (37.8%) 16 (41.0%) 9 (33.3%) .0.05
4-5 41 (62.1%) 23 (59.0%) 18 (66.6%)
Mortality 10 (15.1%) 8 (20.5%) 2 (7.4%) .0.05
N: number; GCS: Glasgow Coma Scale; GOS: Glasgow Outcome Scale.
Table 3 - Incidence of hormone disturbances indicating
anterior pituitary dysfunction in patients with SAH.
Hormone disturbance n %
Isolated gonadotrophic 10 15.1
Isolated somatotrophic 9 13.6
Isolated corticotrophic 1 1.5
Prolactin 0 0.0
Isolated thyrotrophic 0 0.0
Somatotrophic + gonadotrophic 4 6.0
Somatotrophic + prolactin 3 4.5
Corticotrophic + gonadotrophic + thyrotrophic 3 4.5
Gonadotrophic + prolactin 3 4.5
Corticotrophic + gonadotrophic 2 3.0
Somatotrophic + thyrotrophic 1 1.5
Corticotrophic + thyrotrophic 1 1.5
Corticotrophic + somatotrophic + gonadotrophic 1 1.5
Total 39 59.0
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stress. They also observed a greater incidence of high
prolactin (14.2%). Regarding thyroid hormones, they
observed high TSH in 14.2% of patients, low T3 in 14.2%
and low T4 in 5.6%, whereas FSH and LH were unaffected.
In a review by Schneider et al. (6) regarding hormonal
dysfunction in SAH, they identified 5 papers on pituitary
dysfunction in late-stage SAH (6 months following ictus)
that included 102 patients. This review found a mean
prevalence of hormonal dysfunction of 47% (37.5-55%) (3-
8,14). Schneider et al. (6) also observed large differences in
the frequency of the different anterior pituitary axes
affected: GH (25.4%) and ACTH (20.5%) deficiencies were
the most common, followed by FSH/LH (5.9%) and TSH
(5.9%) deficiencies. Multiple deficiencies were detected in
8.8% of patients. In contrast, Klose et al. (17) evaluated 62
patients at a mean of 14 months after ictus and detected a
post-SAH prevalence of hormonal dysfunction of 13%. To
improve the lack of knowledge that exists today on
endocrine deficiency following SAH, we are still following
up with this series of patients. Our aims are to evaluate their
later pituitary function to corroborate not only the incidence
but also the prevalence of this disorder as well as to
correlate pituitary dysfunction with delayed functional
state.
We believe that our study found a higher rate of
hormonal dysfunction (incidence) than papers analyzing
the late phase after SAH (prevalence) because most pituitary
dysfunctions are transient; i.e., hormonal dysfunction is
greater when examined in the first days after SAH and
decreases over time. An analogous situation has been
observed in hormonal evaluations in traumatic brain injury
(TBI) patients, in which a trend toward improvement in
hormonal dysfunctions occurs in some patients over a year-
long assessment (6,19). Aimaretti et al. (8) observed a
reduction in the prevalence of hormonal dysfunction
following SAH from 47% at three months to 38% at 12
months.
It is important to note that some pituitary functions are
better evaluated using a combined TRH-LHRH-arginine
(ARG) test and an insulin tolerance test (ITT) instead of
basal measures. Some authors have used those tests in
patients with SAH between 12 and 72 months after the ictus
(5), but it is difficult and dangerous to perform those tests in
the acute phase. Thus, those tests were not performed in our
group.
In this paper, we did not evaluate posterior pituitary
deficiency, which is primarily represented by sodium
imbalance secondary to antidiuretic hormone (ADH) dys-
function, because this dysfunction is already a well-known
condition in patients with SAH and patients submitted to
neurosurgery approaches.
In the present study, hormonal evaluation in the first two
weeks after SAH revealed a high incidence of pituitary
dysfunction that was not related to prognosis or hospitali-
zation period.
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